Ocular Therapeutix announced it will present additional data from its SOL-1 Phase 3 trial of AXPAXLI (OTX-TKI), a treatment for wet age-related macular degeneration (wet AMD), at multiple scientific conferences in April 2026. Key presentations will occur at the 14th Annual Vit-Buckle Society Meeting in Las Vegas and the Congreso Nacional de Oftalmologia in Buenos Aires, featuring company executives and leading doctors. This data could impact the future treatment landscape for retinal diseases, including diabetic retinal disease and wet AMD. Investors and stakeholders will watch these presentations closely for insights into the drug's clinical progress and potential market impact.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
